{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T15:14:36Z","timestamp":1788621276510,"version":"build-2803163510"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplant Immunology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.trim.2026.102420","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:05:11Z","timestamp":1784246711000},"page":"102420","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Safety and efficacy of immune checkpoint inhibitors as a bridge to allogeneic hematopoietic stem cell transplantation in classical Hodgkin lymphoma: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"98","author":[{"given":"Pragya","family":"Jain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viraj","family":"Panchal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vedant","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nency","family":"Ganatra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivam","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ansy","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junaid","family":"Anwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trim.2026.102420_bb0005","article-title":"ASTCT clinical practice recommendations for transplantation in classical Hodgkin lymphoma","volume":"32","author":"Ahmed","year":"2025","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.trim.2026.102420_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.hoc.2025.12.003","article-title":"The role of stem cell transplantation in Hodgkin lymphoma","volume":"40","author":"Alharthy","year":"2026","journal-title":"Hematol. Oncol. Clin. North Am."},{"issue":"10","key":"10.1016\/j.trim.2026.102420_bb0015","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/s41409-023-02073-6","article-title":"Safety and efficacy of immune checkpoint inhibitors after allogeneic hematopoietic cell transplantation","volume":"58","author":"Alkhaldi","year":"2023","journal-title":"Bone Marrow Transplant."},{"issue":"1","key":"10.1016\/j.trim.2026.102420_bb0020","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/bloodadvances.2019000736","article-title":"Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT","volume":"4","author":"Badar","year":"2020","journal-title":"Blood Adv."},{"issue":"10310","key":"10.1016\/j.trim.2026.102420_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)32207-8","article-title":"Classical Hodgkin lymphoma","volume":"398","author":"Brice","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.trim.2026.102420_bb0030","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1203470","article-title":"Tackling the dysregulated immune-checkpoints in classical Hodgkin lymphoma: bidirectional regulations between the microenvironment and Hodgkin\/reed-Sternberg cells","volume":"13","author":"Cellini","year":"2023","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.trim.2026.102420_bb0035","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ccell.2020.07.004","article-title":"Clinical challenges of immune checkpoint inhibitors","volume":"38","author":"de Miguel","year":"2020","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.trim.2026.102420_bb0040","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1182\/bloodadvances.2019001336","article-title":"Checkpoint inhibition before haploidentical transplantation with posttransplant cyclophosphamide in Hodgkin lymphoma","volume":"4","author":"de Philippis","year":"2020","journal-title":"Blood Adv."},{"issue":"2","key":"10.1016\/j.trim.2026.102420_bb0045","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3390\/curroncol32020118","article-title":"Outcomes of allogeneic stem cell transplant in patients with relapsed\/refractory Hodgkin lymphoma","volume":"32","author":"Ge","year":"2025","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.trim.2026.102420_bb0050","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1491330","article-title":"The influence of immune checkpoint blockade on the outcomes of allogeneic hematopoietic stem cell transplantation","volume":"15","author":"Hu","year":"2024","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.trim.2026.102420_bb0055","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1007\/s12185-020-02960-4","article-title":"Safety and efficacy of anti-programmed cell death-1 monoclonal antibodies before and after allogeneic hematopoietic cell transplantation for relapsed or refractory Hodgkin lymphoma: a multicenter retrospective study","volume":"112","author":"Ito","year":"2020","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.trim.2026.102420_bb0060","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.761448","article-title":"T cell subsets in graft versus host disease and graft versus tumor","volume":"12","author":"Jiang","year":"2021","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.trim.2026.102420_bb0065","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2024.284968","article-title":"PD-1 blockade and allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma, a matter of time: a national study on behalf of the Soci\u00e9t\u00e9 francophone de Greffe de Moelle et de Th\u00e9rapie Cellulaire","volume":"109","author":"Kaphan","year":"2023","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.trim.2026.102420_bb0070","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2019000847","article-title":"The immune landscape and response to immune checkpoint blockade therapy in lymphoma","volume":"135","author":"Kline","year":"2020","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.trim.2026.102420_bb0075","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201979","article-title":"Immune checkpoint inhibitors","volume":"218","author":"Kroemer","year":"2021","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.trim.2026.102420_bb0080","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jconrel.2021.01.009","article-title":"The right timing, right combination, right sequence, and right delivery for Cancer immunotherapy","volume":"331","author":"Kwon","year":"2021","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.trim.2026.102420_bb0085","doi-asserted-by":"crossref","first-page":"100146","DOI":"10.1016\/j.cellin.2024.100146","article-title":"PD-1-mediated inhibition of T cell activation: mechanisms and strategies for cancer combination immunotherapy","volume":"3","author":"Liu","year":"2024","journal-title":"Cell Insight"},{"issue":"3","key":"10.1016\/j.trim.2026.102420_bb0090","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/cbf.3463","article-title":"Epigenetic abnormalities of classical Hodgkin lymphoma and its effect on immune escape","volume":"38","author":"Liu","year":"2020","journal-title":"Cell Biochem. Funct."},{"key":"10.1016\/j.trim.2026.102420_bb0095","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ejca.2019.04.006","article-title":"Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation","volume":"115","author":"Manson","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.trim.2026.102420_bb0100","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1054314","article-title":"The role of transplantation in Hodgkin lymphoma","volume":"12","author":"Maranzano","year":"2023","journal-title":"Front. Oncol."},{"issue":"8","key":"10.1016\/j.trim.2026.102420_bb0105","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1016\/j.bbmt.2020.02.003","article-title":"Potential survival benefit for patients receiving allogeneic hematopoietic stem cell transplantation after nivolumab therapy for relapse\/refractory Hodgkin lymphoma: Real-life experience in Spain","volume":"26","author":"Mart\u00ednez","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"9","key":"10.1016\/j.trim.2026.102420_bb0110","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1038\/s41375-021-01193-6","article-title":"Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma","volume":"35","author":"Merryman","year":"2021","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.trim.2026.102420_bb0115","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1182\/blood-2016-09-738385","article-title":"Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed\/refractory lymphoma","volume":"129","author":"Merryman","year":"2017","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.trim.2026.102420_bb0120","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241210095","article-title":"Classical Hodgkin lymphoma: from past to future\u2014a comprehensive review of pathophysiology and therapeutic advances","volume":"24","author":"Munir","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.trim.2026.102420_bb0125","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1403936","article-title":"Graft-versus-tumor effect of post-transplant cyclophosphamide-based allogeneic hematopoietic cell transplantation","volume":"15","author":"Nakamae","year":"2024","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.trim.2026.102420_bb0130","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1080\/17474086.2025.2545336","article-title":"Reduced-intensity conditioning for allogeneic transplantation in classical Hodgkin lymphoma","volume":"18","author":"Narvel","year":"2025","journal-title":"Expert Rev. Hematol."},{"issue":"1","key":"10.1016\/j.trim.2026.102420_bb0135","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1182\/hematology.2024000575","article-title":"When to use stem cell transplantation for classical Hodgkin lymphoma","volume":"2024","author":"Perales","year":"2024","journal-title":"Hematology"},{"issue":"8","key":"10.1016\/j.trim.2026.102420_bb0140","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2024027197","article-title":"Outcomes of allogeneic HCT in Hodgkin lymphoma in the era of checkpoint inhibitors: a joint CIBMTR and EBMT analysis","volume":"146","author":"Perales","year":"2025","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.trim.2026.102420_bb0145","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1080\/14737140.2021.1918548","article-title":"Immune checkpoint inhibition in classical hodgkin lymphoma","volume":"21","author":"Pezeshki","year":"2021","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"18","key":"10.1016\/j.trim.2026.102420_bb0150","doi-asserted-by":"crossref","first-page":"4509","DOI":"10.3390\/cancers15184509","article-title":"Optimizing treatment for relapsed\/refractory classic Hodgkin lymphoma in the era of immunotherapy","volume":"15","author":"Randall","year":"2023","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.trim.2026.102420_bb0155","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41409-019-0640-z","article-title":"Allogeneic stem cell transplantation improves survival in relapsed Hodgkin lymphoma patients achieving complete remission after salvage treatment","volume":"55","author":"Rivas","year":"2020","journal-title":"Bone Marrow Transplant."},{"issue":"7","key":"10.1016\/j.trim.2026.102420_bb0160","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.3390\/cancers14071738","article-title":"Autologous stem cell transplantation in Hodgkin lymphoma\u2014latest advances in the era of novel therapies","volume":"14","author":"Samara","year":"2022","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.trim.2026.102420_bb0165","first-page":"3044","article-title":"Immune checkpoint inhibitors in Cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr. Oncol. (Toronto, Ont.)"},{"issue":"4","key":"10.1016\/j.trim.2026.102420_bb0170","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1080\/10428194.2024.2438805","article-title":"Allogeneic stem cell transplantation against aggressive lymphomas: graft-versus-lymphoma effects in peripheral T-cell lymphoma and diffuse large B-cell lymphoma after myeloablative conditioning","volume":"66","author":"Shumilov","year":"2024","journal-title":"Leuk. Lymphoma"},{"issue":"8","key":"10.1016\/j.trim.2026.102420_bb0175","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2025028617","article-title":"Challenges in GVHD and GVL after hematopoietic stem cell transplantation for myeloid malignancies","volume":"146","author":"Soci\u00e9","year":"2025","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.trim.2026.102420_bb0180","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2024015048","article-title":"Improved overall survival with checkpoint inhibition and allogeneic transplantation in relapsed Hodgkin lymphoma","volume":"9","author":"Tabbara","year":"2025","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.trim.2026.102420_bb0185","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20182232","article-title":"PD-1 restraint of regulatory T cell suppressive activity is critical for immune tolerance","volume":"218","author":"Tan","year":"2021","journal-title":"J. Exp. Med."},{"issue":"13","key":"10.1016\/j.trim.2026.102420_bb0190","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.3390\/cancers14133222","article-title":"Novel approaches in molecular characterization of classical Hodgkin lymphoma","volume":"14","author":"van Bladel","year":"2022","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.trim.2026.102420_bb0195","first-page":"145","article-title":"Real-world outcomes of autologous and allogeneic hematopoietic stem cell transplantation for relapsed\/refractory Hodgkin lymphoma in the era of novel therapies: a Canadian perspective","volume":"28","author":"Veilleux","year":"2022","journal-title":"Transpl. Cell. Therapy"},{"issue":"10","key":"10.1016\/j.trim.2026.102420_bb0200","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.3390\/cancers12102887","article-title":"Therapeutic updates for relapsed and refractory classical Hodgkin lymphoma","volume":"12","author":"Voorhees","year":"2020","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.trim.2026.102420_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.trecan.2023.04.002","article-title":"Immune mechanisms of toxicity from checkpoint inhibitors","volume":"9","author":"Wang","year":"2023","journal-title":"Trends Cancer"},{"issue":"6","key":"10.1016\/j.trim.2026.102420_bb0210","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1042\/EBC20230001","article-title":"The role of IFN-\u03b3-signalling in response to immune checkpoint blockade therapy","volume":"67","author":"Wong","year":"2023","journal-title":"Essays Biochem."},{"issue":"4","key":"10.1016\/j.trim.2026.102420_bb0215","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s11899-020-00589-y","article-title":"PD-1\/PD-L1 pathway and its blockade in patients with classic Hodgkin lymphoma and non-Hodgkin large-cell lymphomas","volume":"15","author":"Xie","year":"2020","journal-title":"Curr. Hematol. Malig. Rep."},{"issue":"1","key":"10.1016\/j.trim.2026.102420_bb0220","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol. Cancer"}],"container-title":["Transplant Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096632742600078X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096632742600078X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T14:55:13Z","timestamp":1788620113000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096632742600078X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":44,"alternative-id":["S096632742600078X"],"URL":"https:\/\/doi.org\/10.1016\/j.trim.2026.102420","relation":{},"ISSN":["0966-3274"],"issn-type":[{"value":"0966-3274","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of immune checkpoint inhibitors as a bridge to allogeneic hematopoietic stem cell transplantation in classical Hodgkin lymphoma: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Transplant Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trim.2026.102420","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102420"}}